| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypospadias | 8 | 2023 | 80 | 2.970 |
Why?
|
| Urinary Bladder, Neurogenic | 7 | 2023 | 46 | 2.780 |
Why?
|
| Circumcision, Male | 5 | 2022 | 25 | 2.060 |
Why?
|
| Lower Urinary Tract Symptoms | 5 | 2018 | 40 | 1.890 |
Why?
|
| Botulinum Toxins, Type A | 4 | 2023 | 164 | 1.870 |
Why?
|
| Urinary Incontinence | 6 | 2020 | 78 | 1.720 |
Why?
|
| Ureteral Obstruction | 9 | 2023 | 105 | 1.690 |
Why?
|
| Bone Morphogenetic Protein 7 | 5 | 2015 | 25 | 1.690 |
Why?
|
| Urology | 5 | 2024 | 87 | 1.410 |
Why?
|
| Nerve Block | 2 | 2022 | 62 | 1.330 |
Why?
|
| Penis | 6 | 2022 | 101 | 1.300 |
Why?
|
| Kidney Diseases | 5 | 2016 | 489 | 1.230 |
Why?
|
| Urinary Bladder | 7 | 2018 | 254 | 1.210 |
Why?
|
| Urethral Diseases | 2 | 2020 | 19 | 0.950 |
Why?
|
| Terminology as Topic | 3 | 2020 | 232 | 0.920 |
Why?
|
| Urination Disorders | 3 | 2014 | 22 | 0.910 |
Why?
|
| Urinary Bladder, Overactive | 2 | 2023 | 30 | 0.890 |
Why?
|
| Disorders of Sex Development | 5 | 2020 | 71 | 0.880 |
Why?
|
| Meningomyelocele | 3 | 2023 | 253 | 0.820 |
Why?
|
| Child | 48 | 2025 | 25789 | 0.810 |
Why?
|
| Postoperative Complications | 6 | 2023 | 3142 | 0.760 |
Why?
|
| Adrenergic alpha-Antagonists | 4 | 2009 | 43 | 0.750 |
Why?
|
| Pain, Postoperative | 3 | 2023 | 272 | 0.740 |
Why?
|
| Muscle, Smooth | 3 | 2010 | 130 | 0.740 |
Why?
|
| Epididymitis | 1 | 2021 | 1 | 0.720 |
Why?
|
| Orchitis | 1 | 2021 | 3 | 0.720 |
Why?
|
| Urodynamics | 7 | 2024 | 40 | 0.720 |
Why?
|
| Vas Deferens | 1 | 2021 | 24 | 0.710 |
Why?
|
| Penile Diseases | 2 | 2020 | 11 | 0.710 |
Why?
|
| Muscarinic Antagonists | 2 | 2013 | 35 | 0.690 |
Why?
|
| Urinary Bladder Diseases | 1 | 2021 | 34 | 0.680 |
Why?
|
| Urinary Fistula | 1 | 2020 | 20 | 0.680 |
Why?
|
| Cutaneous Fistula | 1 | 2020 | 23 | 0.670 |
Why?
|
| Adrenal Hyperplasia, Congenital | 4 | 2022 | 34 | 0.660 |
Why?
|
| Constipation | 2 | 2020 | 128 | 0.650 |
Why?
|
| Parents | 4 | 2022 | 1078 | 0.650 |
Why?
|
| Male | 57 | 2025 | 64922 | 0.640 |
Why?
|
| Dwarfism | 1 | 2020 | 103 | 0.640 |
Why?
|
| Limb Deformities, Congenital | 1 | 2020 | 112 | 0.640 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2021 | 79 | 0.630 |
Why?
|
| Urination | 3 | 2021 | 27 | 0.620 |
Why?
|
| Humans | 85 | 2025 | 132061 | 0.620 |
Why?
|
| Urinary Bladder Neck Obstruction | 3 | 2009 | 30 | 0.620 |
Why?
|
| Urinary Tract Infections | 2 | 2023 | 317 | 0.610 |
Why?
|
| Pain Measurement | 1 | 2021 | 354 | 0.610 |
Why?
|
| Adolescent | 30 | 2025 | 20562 | 0.600 |
Why?
|
| Craniofacial Abnormalities | 1 | 2020 | 253 | 0.590 |
Why?
|
| Urogenital Abnormalities | 1 | 2020 | 164 | 0.580 |
Why?
|
| Wolfram Syndrome | 1 | 2018 | 1 | 0.580 |
Why?
|
| Testis | 1 | 2020 | 422 | 0.580 |
Why?
|
| Pons | 1 | 2018 | 34 | 0.570 |
Why?
|
| Ureter | 5 | 2023 | 99 | 0.560 |
Why?
|
| Child, Preschool | 27 | 2025 | 14751 | 0.550 |
Why?
|
| Enterostomy | 1 | 2017 | 6 | 0.540 |
Why?
|
| Deamino Arginine Vasopressin | 4 | 2018 | 9 | 0.520 |
Why?
|
| Urinary Reservoirs, Continent | 4 | 2001 | 24 | 0.510 |
Why?
|
| Urinary Tract | 2 | 2014 | 62 | 0.490 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 471 | 0.480 |
Why?
|
| Incidence | 10 | 2025 | 3380 | 0.480 |
Why?
|
| Propofol | 1 | 2016 | 50 | 0.470 |
Why?
|
| Kidney | 5 | 2020 | 1331 | 0.470 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2016 | 81 | 0.460 |
Why?
|
| Kidney Tubules, Distal | 1 | 2015 | 17 | 0.460 |
Why?
|
| Nocturnal Enuresis | 2 | 2018 | 3 | 0.450 |
Why?
|
| Infant | 18 | 2025 | 13064 | 0.440 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2015 | 74 | 0.440 |
Why?
|
| Hypnotics and Sedatives | 1 | 2016 | 136 | 0.440 |
Why?
|
| Vesico-Ureteral Reflux | 4 | 2023 | 85 | 0.430 |
Why?
|
| Urinary Tract Physiological Phenomena | 1 | 2014 | 2 | 0.430 |
Why?
|
| Treatment Outcome | 16 | 2023 | 13028 | 0.430 |
Why?
|
| Doxazosin | 3 | 2004 | 28 | 0.430 |
Why?
|
| Prospective Studies | 9 | 2022 | 6567 | 0.430 |
Why?
|
| Mandelic Acids | 1 | 2013 | 6 | 0.420 |
Why?
|
| Spinal Dysraphism | 2 | 2017 | 274 | 0.420 |
Why?
|
| Transforming Growth Factor beta | 2 | 2013 | 473 | 0.400 |
Why?
|
| Neuromuscular Agents | 1 | 2014 | 66 | 0.400 |
Why?
|
| Evidence-Based Medicine | 3 | 2016 | 662 | 0.400 |
Why?
|
| Double-Blind Method | 4 | 2023 | 1659 | 0.400 |
Why?
|
| Urinary Retention | 2 | 2011 | 19 | 0.400 |
Why?
|
| Societies, Medical | 2 | 2015 | 778 | 0.390 |
Why?
|
| Kidney Pelvis | 4 | 2012 | 45 | 0.390 |
Why?
|
| Urogenital System | 2 | 2025 | 35 | 0.390 |
Why?
|
| Histone Deacetylases | 1 | 2013 | 122 | 0.380 |
Why?
|
| Ureterocele | 2 | 2004 | 4 | 0.380 |
Why?
|
| Retrospective Studies | 22 | 2023 | 17419 | 0.360 |
Why?
|
| Child Behavior | 1 | 2013 | 236 | 0.360 |
Why?
|
| Smad1 Protein | 1 | 2011 | 22 | 0.350 |
Why?
|
| Midazolam | 1 | 2011 | 44 | 0.350 |
Why?
|
| Female | 41 | 2025 | 70712 | 0.340 |
Why?
|
| Multicystic Dysplastic Kidney | 2 | 2014 | 3 | 0.340 |
Why?
|
| Urinary Diversion | 2 | 2001 | 41 | 0.340 |
Why?
|
| Anti-Anxiety Agents | 1 | 2011 | 77 | 0.330 |
Why?
|
| Ultrasonography, Prenatal | 7 | 2008 | 1009 | 0.310 |
Why?
|
| Consensus | 4 | 2024 | 650 | 0.300 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2021 | 215 | 0.300 |
Why?
|
| Antidiuretic Agents | 1 | 2008 | 1 | 0.300 |
Why?
|
| Phenylpropanolamine | 1 | 2008 | 4 | 0.300 |
Why?
|
| Cresols | 1 | 2008 | 10 | 0.300 |
Why?
|
| Ventilators, Mechanical | 1 | 2008 | 40 | 0.290 |
Why?
|
| Cryptorchidism | 1 | 2008 | 37 | 0.290 |
Why?
|
| Hydronephrosis | 4 | 2014 | 37 | 0.280 |
Why?
|
| Follow-Up Studies | 9 | 2020 | 5409 | 0.280 |
Why?
|
| Benzhydryl Compounds | 1 | 2008 | 68 | 0.280 |
Why?
|
| Stress, Psychological | 1 | 2013 | 574 | 0.280 |
Why?
|
| Oxygen Consumption | 1 | 2008 | 305 | 0.270 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 573 | 0.270 |
Why?
|
| Urethra | 2 | 2022 | 89 | 0.270 |
Why?
|
| Drug Therapy, Combination | 4 | 2021 | 1180 | 0.270 |
Why?
|
| Anesthesiology | 1 | 2008 | 105 | 0.260 |
Why?
|
| Diverticulum | 1 | 2007 | 30 | 0.260 |
Why?
|
| Anxiety | 2 | 2020 | 987 | 0.240 |
Why?
|
| Adult | 14 | 2023 | 31568 | 0.240 |
Why?
|
| War-Related Injuries | 1 | 2025 | 2 | 0.240 |
Why?
|
| Chromosome Aberrations | 1 | 2008 | 589 | 0.240 |
Why?
|
| Hemorrhagic Fever, Ebola | 2 | 2016 | 59 | 0.240 |
Why?
|
| Young Adult | 7 | 2020 | 9957 | 0.230 |
Why?
|
| Mental Disorders | 1 | 2013 | 884 | 0.230 |
Why?
|
| Kidney Transplantation | 2 | 2023 | 570 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 5 | 2020 | 4757 | 0.220 |
Why?
|
| Caregivers | 2 | 2020 | 595 | 0.220 |
Why?
|
| Disease Outbreaks | 2 | 2016 | 329 | 0.220 |
Why?
|
| Growth Substances | 1 | 2004 | 109 | 0.220 |
Why?
|
| Cohort Studies | 6 | 2020 | 5164 | 0.210 |
Why?
|
| Surveys and Questionnaires | 5 | 2024 | 3990 | 0.200 |
Why?
|
| Quality of Life | 4 | 2022 | 2137 | 0.200 |
Why?
|
| Nitric Oxide Synthase | 1 | 2003 | 175 | 0.200 |
Why?
|
| Testicular Hormones | 1 | 2002 | 4 | 0.200 |
Why?
|
| Androstenedione | 1 | 2002 | 15 | 0.200 |
Why?
|
| Growth Inhibitors | 1 | 2002 | 37 | 0.190 |
Why?
|
| Delphi Technique | 1 | 2024 | 240 | 0.190 |
Why?
|
| Cells, Cultured | 4 | 2013 | 3036 | 0.190 |
Why?
|
| Age Factors | 6 | 2019 | 2912 | 0.190 |
Why?
|
| Insurance Coverage | 1 | 2003 | 124 | 0.190 |
Why?
|
| Cloaca | 2 | 2020 | 15 | 0.190 |
Why?
|
| Intestines | 2 | 2012 | 603 | 0.190 |
Why?
|
| Inflammation Mediators | 1 | 2003 | 240 | 0.180 |
Why?
|
| Infant, Newborn | 12 | 2019 | 8549 | 0.180 |
Why?
|
| Pelvic Neoplasms | 1 | 2022 | 23 | 0.180 |
Why?
|
| Lipopolysaccharides | 1 | 2003 | 306 | 0.180 |
Why?
|
| Fascia | 1 | 2001 | 16 | 0.180 |
Why?
|
| Spinal Neoplasms | 1 | 2022 | 75 | 0.170 |
Why?
|
| Obesity | 1 | 2013 | 2391 | 0.170 |
Why?
|
| Sex Factors | 2 | 2018 | 1353 | 0.170 |
Why?
|
| Analgesics | 1 | 2022 | 127 | 0.170 |
Why?
|
| Constriction, Pathologic | 2 | 2023 | 237 | 0.170 |
Why?
|
| Ibuprofen | 1 | 2021 | 41 | 0.170 |
Why?
|
| Sacrococcygeal Region | 1 | 2020 | 40 | 0.170 |
Why?
|
| Short Bowel Syndrome | 1 | 2001 | 66 | 0.170 |
Why?
|
| Hydrocodone | 1 | 2021 | 37 | 0.170 |
Why?
|
| Teratoma | 1 | 2022 | 132 | 0.170 |
Why?
|
| Blood Flow Velocity | 1 | 2022 | 442 | 0.170 |
Why?
|
| Apoptosis | 3 | 2014 | 1892 | 0.170 |
Why?
|
| Animals | 14 | 2020 | 34882 | 0.160 |
Why?
|
| Glycoproteins | 1 | 2002 | 375 | 0.160 |
Why?
|
| Urologic Surgical Procedures | 5 | 2018 | 63 | 0.160 |
Why?
|
| Puberty | 1 | 2020 | 104 | 0.160 |
Why?
|
| Hirschsprung Disease | 1 | 2020 | 38 | 0.160 |
Why?
|
| Molecular Weight | 1 | 2020 | 309 | 0.160 |
Why?
|
| Acidosis | 1 | 2001 | 101 | 0.160 |
Why?
|
| Stomach | 2 | 1999 | 273 | 0.160 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 140 | 0.160 |
Why?
|
| Fibrosis | 3 | 2016 | 423 | 0.160 |
Why?
|
| Cytokines | 2 | 2020 | 1358 | 0.160 |
Why?
|
| Hydrocephalus | 1 | 2023 | 277 | 0.160 |
Why?
|
| Drug Combinations | 1 | 2021 | 280 | 0.160 |
Why?
|
| Anesthetics | 1 | 2020 | 79 | 0.160 |
Why?
|
| Acetaminophen | 1 | 2021 | 97 | 0.160 |
Why?
|
| Urinary Catheterization | 1 | 2000 | 86 | 0.160 |
Why?
|
| Bladder Exstrophy | 1 | 1999 | 13 | 0.160 |
Why?
|
| Ebolavirus | 2 | 2016 | 47 | 0.150 |
Why?
|
| Kidney Tubules | 2 | 2016 | 74 | 0.150 |
Why?
|
| Urologists | 1 | 2019 | 12 | 0.150 |
Why?
|
| Ileum | 2 | 2016 | 129 | 0.150 |
Why?
|
| Cystadenoma, Papillary | 1 | 1998 | 4 | 0.150 |
Why?
|
| Gastric Mucosa | 2 | 1999 | 491 | 0.150 |
Why?
|
| Patients | 1 | 2020 | 128 | 0.150 |
Why?
|
| Clinical Alarms | 1 | 2018 | 9 | 0.150 |
Why?
|
| Mice | 9 | 2016 | 18507 | 0.150 |
Why?
|
| Renal Insufficiency | 1 | 2001 | 256 | 0.150 |
Why?
|
| Drainage | 1 | 2000 | 264 | 0.140 |
Why?
|
| Attitude to Health | 1 | 2020 | 259 | 0.140 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2019 | 60 | 0.140 |
Why?
|
| Child Health | 1 | 2019 | 68 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2022 | 1450 | 0.140 |
Why?
|
| Pediatricians | 1 | 2019 | 73 | 0.140 |
Why?
|
| Physical Examination | 1 | 2019 | 166 | 0.140 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 1491 | 0.140 |
Why?
|
| Enuresis | 3 | 2008 | 6 | 0.140 |
Why?
|
| Gonadal Dysgenesis, 46,XY | 1 | 2017 | 17 | 0.140 |
Why?
|
| Anesthesia | 1 | 2020 | 217 | 0.140 |
Why?
|
| Testicular Neoplasms | 1 | 1998 | 131 | 0.140 |
Why?
|
| Enema | 1 | 2017 | 44 | 0.130 |
Why?
|
| Preoperative Period | 1 | 2017 | 92 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2021 | 482 | 0.130 |
Why?
|
| Nephrectomy | 1 | 2018 | 178 | 0.130 |
Why?
|
| Organ Size | 1 | 2018 | 449 | 0.130 |
Why?
|
| Risk Assessment | 5 | 2019 | 3736 | 0.130 |
Why?
|
| Testosterone | 1 | 2002 | 611 | 0.130 |
Why?
|
| NFATC Transcription Factors | 2 | 2014 | 38 | 0.130 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 242 | 0.130 |
Why?
|
| Disease Models, Animal | 4 | 2016 | 4688 | 0.130 |
Why?
|
| Angiopoietin-1 | 1 | 2016 | 7 | 0.130 |
Why?
|
| Gene Expression | 2 | 2016 | 1558 | 0.120 |
Why?
|
| Ureteral Neoplasms | 1 | 2016 | 26 | 0.120 |
Why?
|
| Symptom Assessment | 1 | 2016 | 111 | 0.120 |
Why?
|
| Fibroblasts | 1 | 2020 | 861 | 0.120 |
Why?
|
| Sexual Development | 3 | 2022 | 24 | 0.120 |
Why?
|
| Spinal Cord | 1 | 2017 | 267 | 0.120 |
Why?
|
| Respiratory Tract Diseases | 1 | 2016 | 80 | 0.120 |
Why?
|
| Epidemics | 1 | 2016 | 59 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 613 | 0.120 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 37 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 307 | 0.110 |
Why?
|
| Self Report | 1 | 2018 | 549 | 0.110 |
Why?
|
| Caspase 3 | 1 | 2015 | 138 | 0.110 |
Why?
|
| Databases, Factual | 3 | 2019 | 1227 | 0.110 |
Why?
|
| RNA, Messenger | 3 | 2013 | 2674 | 0.110 |
Why?
|
| Fetal Diseases | 1 | 1998 | 462 | 0.110 |
Why?
|
| Intestinal Mucosa | 1 | 1999 | 794 | 0.110 |
Why?
|
| Adenoma | 1 | 2016 | 147 | 0.110 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2014 | 58 | 0.110 |
Why?
|
| Organogenesis | 1 | 2014 | 82 | 0.110 |
Why?
|
| Sympathomimetics | 1 | 2014 | 13 | 0.110 |
Why?
|
| Prevalence | 1 | 2021 | 2658 | 0.110 |
Why?
|
| ADAM Proteins | 1 | 2014 | 84 | 0.100 |
Why?
|
| Neural Tube Defects | 1 | 2017 | 358 | 0.100 |
Why?
|
| Transcription, Genetic | 3 | 2014 | 1422 | 0.100 |
Why?
|
| Lymphangitis | 1 | 2013 | 5 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 724 | 0.100 |
Why?
|
| Bandages | 1 | 2013 | 56 | 0.100 |
Why?
|
| Hemostatics | 1 | 2013 | 62 | 0.100 |
Why?
|
| Urography | 2 | 2011 | 32 | 0.100 |
Why?
|
| Missouri | 1 | 2013 | 42 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2015 | 431 | 0.100 |
Why?
|
| Reference Standards | 1 | 2014 | 242 | 0.100 |
Why?
|
| Granuloma | 1 | 2013 | 65 | 0.100 |
Why?
|
| Epinephrine | 1 | 2014 | 155 | 0.100 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 115 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2014 | 876 | 0.100 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2012 | 6 | 0.090 |
Why?
|
| Research Design | 1 | 2017 | 741 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 357 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2016 | 568 | 0.090 |
Why?
|
| Disease Progression | 2 | 2017 | 2224 | 0.090 |
Why?
|
| Robotic Surgical Procedures | 1 | 2016 | 223 | 0.090 |
Why?
|
| Fecal Incontinence | 1 | 2012 | 78 | 0.090 |
Why?
|
| Injections, Intralesional | 1 | 2011 | 47 | 0.090 |
Why?
|
| Pediatrics | 2 | 2024 | 1213 | 0.090 |
Why?
|
| Cystoscopy | 1 | 2011 | 45 | 0.090 |
Why?
|
| Genitalia | 2 | 2021 | 38 | 0.090 |
Why?
|
| Phenotype | 1 | 2020 | 4529 | 0.080 |
Why?
|
| Physical Therapy Modalities | 1 | 2011 | 56 | 0.080 |
Why?
|
| Signal Transduction | 4 | 2016 | 4703 | 0.080 |
Why?
|
| Laparoscopy | 1 | 2016 | 523 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2010 | 60 | 0.080 |
Why?
|
| Crohn Disease | 1 | 2013 | 291 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 393 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2013 | 519 | 0.080 |
Why?
|
| Biomechanical Phenomena | 1 | 2010 | 259 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 3834 | 0.080 |
Why?
|
| Heart Arrest | 1 | 2014 | 374 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2008 | 367 | 0.080 |
Why?
|
| Tolterodine Tartrate | 1 | 2008 | 2 | 0.070 |
Why?
|
| Capsules | 1 | 2008 | 22 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2011 | 698 | 0.070 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2009 | 74 | 0.070 |
Why?
|
| Behavior Therapy | 1 | 2011 | 269 | 0.070 |
Why?
|
| Middle Aged | 6 | 2017 | 28964 | 0.070 |
Why?
|
| Comorbidity | 1 | 2013 | 1609 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 3761 | 0.070 |
Why?
|
| Renal Agents | 2 | 1998 | 5 | 0.070 |
Why?
|
| Psychometrics | 2 | 2022 | 682 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1294 | 0.070 |
Why?
|
| Brain | 1 | 2019 | 3183 | 0.070 |
Why?
|
| Sierra Leone | 2 | 2016 | 20 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2013 | 1694 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2014 | 1610 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 845 | 0.060 |
Why?
|
| Cell Division | 2 | 2004 | 743 | 0.060 |
Why?
|
| Afghan Campaign 2001- | 1 | 2025 | 118 | 0.060 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2025 | 126 | 0.060 |
Why?
|
| Blast Injuries | 1 | 2025 | 61 | 0.060 |
Why?
|
| Injury Severity Score | 1 | 2025 | 230 | 0.060 |
Why?
|
| Pregnancy | 4 | 2008 | 7566 | 0.050 |
Why?
|
| Anemia, Sickle Cell | 1 | 2008 | 329 | 0.050 |
Why?
|
| Hospitals, Maternity | 1 | 2003 | 8 | 0.050 |
Why?
|
| HIV Infections | 1 | 2016 | 2035 | 0.050 |
Why?
|
| Midwestern United States | 1 | 2003 | 17 | 0.050 |
Why?
|
| Utilization Review | 1 | 2003 | 40 | 0.050 |
Why?
|
| Cell Proliferation | 3 | 2020 | 2508 | 0.050 |
Why?
|
| Guanidines | 1 | 2003 | 23 | 0.050 |
Why?
|
| Collagen Type III | 1 | 2003 | 25 | 0.050 |
Why?
|
| Health Care Sector | 1 | 2003 | 20 | 0.050 |
Why?
|
| Risk Factors | 2 | 2017 | 10941 | 0.050 |
Why?
|
| Hospitals, Community | 1 | 2003 | 55 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2003 | 93 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2003 | 135 | 0.050 |
Why?
|
| Medically Uninsured | 1 | 2003 | 78 | 0.050 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2002 | 11 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 768 | 0.050 |
Why?
|
| Virilism | 1 | 2022 | 14 | 0.050 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2023 | 58 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 3091 | 0.050 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2002 | 43 | 0.050 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2022 | 65 | 0.050 |
Why?
|
| United States | 3 | 2025 | 11658 | 0.050 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2001 | 34 | 0.040 |
Why?
|
| Reference Values | 1 | 2002 | 708 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2003 | 534 | 0.040 |
Why?
|
| Training Support | 1 | 2020 | 18 | 0.040 |
Why?
|
| Medicaid | 1 | 2003 | 251 | 0.040 |
Why?
|
| Nurse Anesthetists | 1 | 2020 | 12 | 0.040 |
Why?
|
| Anesthesia, Caudal | 1 | 2020 | 15 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 664 | 0.040 |
Why?
|
| Rectum | 1 | 2001 | 114 | 0.040 |
Why?
|
| Urogenital Surgical Procedures | 1 | 2020 | 11 | 0.040 |
Why?
|
| Anesthesiologists | 1 | 2020 | 41 | 0.040 |
Why?
|
| Aged | 5 | 2016 | 21406 | 0.040 |
Why?
|
| Cause of Death | 1 | 2023 | 510 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2003 | 471 | 0.040 |
Why?
|
| Pelvic Floor | 1 | 2020 | 39 | 0.040 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2000 | 21 | 0.040 |
Why?
|
| Uncertainty | 1 | 2020 | 101 | 0.040 |
Why?
|
| Pulmonary Alveoli | 1 | 2020 | 141 | 0.040 |
Why?
|
| Operative Time | 1 | 2020 | 195 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2016 | 2445 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 3014 | 0.040 |
Why?
|
| Recurrence | 1 | 2003 | 1470 | 0.040 |
Why?
|
| Ploidies | 1 | 1999 | 36 | 0.040 |
Why?
|
| Genitalia, Male | 1 | 2019 | 35 | 0.040 |
Why?
|
| Program Development | 1 | 2020 | 192 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 236 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2020 | 238 | 0.040 |
Why?
|
| Health Status | 1 | 2021 | 402 | 0.040 |
Why?
|
| Dextrans | 1 | 2018 | 48 | 0.040 |
Why?
|
| Hormones | 1 | 2019 | 170 | 0.040 |
Why?
|
| Registries | 1 | 2025 | 1572 | 0.040 |
Why?
|
| Documentation | 1 | 2019 | 120 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 257 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2019 | 435 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 1999 | 264 | 0.030 |
Why?
|
| Gastrins | 1 | 1997 | 31 | 0.030 |
Why?
|
| Dilatation, Pathologic | 2 | 2008 | 89 | 0.030 |
Why?
|
| Hyaluronic Acid | 1 | 2018 | 108 | 0.030 |
Why?
|
| Time Factors | 2 | 2017 | 6448 | 0.030 |
Why?
|
| Reoperation | 1 | 2020 | 853 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2021 | 669 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2018 | 152 | 0.030 |
Why?
|
| Infectious Disease Incubation Period | 1 | 2016 | 9 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1997 | 451 | 0.030 |
Why?
|
| Urine | 1 | 1997 | 90 | 0.030 |
Why?
|
| Surgeons | 1 | 2020 | 286 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2016 | 121 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 332 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 133 | 0.030 |
Why?
|
| Microcirculation | 1 | 2016 | 117 | 0.030 |
Why?
|
| Malaria | 1 | 2016 | 99 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 272 | 0.030 |
Why?
|
| Fatigue | 1 | 2016 | 201 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 257 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 7102 | 0.030 |
Why?
|
| Colon | 1 | 1997 | 370 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 268 | 0.030 |
Why?
|
| Aquaporin 2 | 1 | 2014 | 6 | 0.030 |
Why?
|
| ADAM10 Protein | 1 | 2014 | 9 | 0.030 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2014 | 7 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 404 | 0.030 |
Why?
|
| Polyuria | 1 | 2014 | 10 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2019 | 777 | 0.030 |
Why?
|
| Calcineurin | 1 | 2014 | 62 | 0.030 |
Why?
|
| Actins | 1 | 2016 | 334 | 0.030 |
Why?
|
| Diarrhea | 1 | 2016 | 330 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 440 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2012 | 2320 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 540 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 415 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 546 | 0.030 |
Why?
|
| Fever | 1 | 2016 | 311 | 0.030 |
Why?
|
| Infusions, Intraosseous | 1 | 2014 | 22 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 1247 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 1284 | 0.030 |
Why?
|
| Lymphedema | 1 | 2013 | 18 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 162 | 0.020 |
Why?
|
| Cadherins | 1 | 2014 | 179 | 0.020 |
Why?
|
| Wnt Signaling Pathway | 1 | 2014 | 205 | 0.020 |
Why?
|
| Ligands | 1 | 2014 | 494 | 0.020 |
Why?
|
| Prednisone | 1 | 2013 | 253 | 0.020 |
Why?
|
| Metronidazole | 1 | 2013 | 157 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2013 | 233 | 0.020 |
Why?
|
| Ureteroscopy | 1 | 2012 | 20 | 0.020 |
Why?
|
| Inflammation | 1 | 2020 | 1517 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2014 | 212 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 381 | 0.020 |
Why?
|
| Depression | 1 | 2020 | 1333 | 0.020 |
Why?
|
| Wolffian Ducts | 1 | 2011 | 10 | 0.020 |
Why?
|
| Benchmarking | 1 | 2012 | 138 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 241 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2020 | 1248 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 1999 | 1539 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2014 | 903 | 0.020 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2009 | 20 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2009 | 57 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1694 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 2146 | 0.020 |
Why?
|
| Solubility | 1 | 2009 | 125 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2009 | 68 | 0.020 |
Why?
|
| Stem Cells | 1 | 2014 | 732 | 0.020 |
Why?
|
| Kidney Calices | 1 | 2008 | 4 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 173 | 0.020 |
Why?
|
| Cell Separation | 1 | 2009 | 223 | 0.020 |
Why?
|
| Nocturia | 1 | 2008 | 1 | 0.020 |
Why?
|
| Protein Transport | 1 | 2009 | 369 | 0.020 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2009 | 189 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 2438 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 294 | 0.020 |
Why?
|
| Hospitalization | 1 | 2016 | 1898 | 0.020 |
Why?
|
| Osmolar Concentration | 2 | 1998 | 157 | 0.020 |
Why?
|
| Administration, Intranasal | 2 | 1998 | 140 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2003 | 1672 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 587 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 3406 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 601 | 0.020 |
Why?
|
| Binding Sites | 1 | 2009 | 1256 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2009 | 1608 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 1280 | 0.010 |
Why?
|
| Pain | 1 | 2008 | 456 | 0.010 |
Why?
|
| Base Sequence | 1 | 2009 | 2899 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 3770 | 0.010 |
Why?
|
| Prognosis | 1 | 2012 | 5009 | 0.010 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2003 | 128 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 749 | 0.010 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2001 | 36 | 0.010 |
Why?
|
| Mutation | 1 | 2014 | 6229 | 0.010 |
Why?
|
| Endoscopy | 1 | 2001 | 289 | 0.010 |
Why?
|
| Prostatic Hyperplasia | 1 | 1999 | 122 | 0.010 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1999 | 93 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 1952 | 0.010 |
Why?
|
| Urinalysis | 1 | 1997 | 69 | 0.010 |
Why?
|
| Probability | 1 | 1997 | 321 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 1998 | 317 | 0.010 |
Why?
|
| Logistic Models | 1 | 1997 | 1838 | 0.010 |
Why?
|